Two Sigma Investments’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Two Sigma Investments’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-37,074	Closed	-$300K	–	4766
2021 Q1	$300K	Buy	+37,074	New	+$404K	﹤0.01%	3325
2020 Q4	–	Sell	-13,000	Closed	-$144K	–	3908
2020 Q3	$144K	Sell	13,000 -25,219	-66%	-$175K	﹤0.01%	2892
2020 Q2	$284K	Buy	+38,219	New	+$256K	﹤0.01%	2416

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's KLDO Position: Q2 2021 in Review

Two Sigma Investments sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2021, closing a stake of 37,074 shares — an estimated $300K sold.

Two Sigma Investments first reported a position in KLDO in Q2 2020 and held it in 3 quarters. The position peaked at $300K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q2 2021.

Two Sigma Investments reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Two Sigma Investments sold 37,074 Kaleido Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $300K.
Two Sigma Investments first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Two Sigma Investments's Kaleido Biosciences, Inc. Common Stock position peaked at $300K in Q1 2021.
71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2021.

Based on Two Sigma Investments's 13F filing for Q2 2021, filed 16 Aug 2021.